1. Home
  2. INTS vs BMRA Comparison

INTS vs BMRA Comparison

Compare INTS & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • BMRA
  • Stock Information
  • Founded
  • INTS 2012
  • BMRA 1971
  • Country
  • INTS United States
  • BMRA United States
  • Employees
  • INTS N/A
  • BMRA N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • INTS Health Care
  • BMRA Health Care
  • Exchange
  • INTS Nasdaq
  • BMRA Nasdaq
  • Market Cap
  • INTS 9.4M
  • BMRA 8.1M
  • IPO Year
  • INTS 2023
  • BMRA N/A
  • Fundamental
  • Price
  • INTS $0.32
  • BMRA $3.09
  • Analyst Decision
  • INTS Strong Buy
  • BMRA
  • Analyst Count
  • INTS 3
  • BMRA 0
  • Target Price
  • INTS $8.50
  • BMRA N/A
  • AVG Volume (30 Days)
  • INTS 2.7M
  • BMRA 26.0K
  • Earning Date
  • INTS 08-07-2025
  • BMRA 04-14-2025
  • Dividend Yield
  • INTS N/A
  • BMRA N/A
  • EPS Growth
  • INTS N/A
  • BMRA N/A
  • EPS
  • INTS N/A
  • BMRA N/A
  • Revenue
  • INTS N/A
  • BMRA $5,678,000.00
  • Revenue This Year
  • INTS N/A
  • BMRA N/A
  • Revenue Next Year
  • INTS N/A
  • BMRA N/A
  • P/E Ratio
  • INTS N/A
  • BMRA N/A
  • Revenue Growth
  • INTS N/A
  • BMRA 5.01
  • 52 Week Low
  • INTS $0.26
  • BMRA $1.93
  • 52 Week High
  • INTS $5.10
  • BMRA $10.16
  • Technical
  • Relative Strength Index (RSI)
  • INTS 37.08
  • BMRA 45.39
  • Support Level
  • INTS $0.28
  • BMRA $3.03
  • Resistance Level
  • INTS $0.32
  • BMRA $3.44
  • Average True Range (ATR)
  • INTS 0.06
  • BMRA 0.19
  • MACD
  • INTS 0.01
  • BMRA 0.01
  • Stochastic Oscillator
  • INTS 7.43
  • BMRA 43.24

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About BMRA Biomerica Inc.

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.

Share on Social Networks: